Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced S… Recruiting

2025-521407-52-00 Advanced Solid Tumors 1 2025-12-16
QUADvance: Advancing Allogeneic Quad-CAR01-T Therapy in Hard-to-Treat B-Cell Cancers Recruiting

2025-521735-36-00 Relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B- 7 2025-12-15
A Phase II Randomized Clinical Trial Comparing Two Cycles Versus Four Cycles of Combination Therapy with Cetuximab, Avelumab, Cisplatin, and… Recruiting

2025-521738-27-00 Recurrent Metastatic Head and Neck Cancer 4 2025-12-15
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid… Recruiting

2025-522395-92-00 metastatic oeso-gastric adenocarcinoma 5 2025-12-15
A clinical study of MK-1084 and other treatments for lung cancer (MK-1084-007) Recruiting

2024-514500-14-00 Participants with KRAS G12C-Mutant, Advanced or Metasta 5 2025-12-15
A study to investigate the safety and efficacy of ONA-255 in participants with advanced cancer Recruiting

2025-522233-62-00 Advanced cancer; breast cancer; metastatic gastric / ga 7 2025-12-12
NeoTISLEGA - A phase Ib trial evaluating the safety and activity of neoadjuvant combination of tislelizumab plus FLOT for resectable esophag… Recruiting

2024-519993-38-00 resectable esophagogastric adenocarcinoma 3 2025-12-12
Open label phase II study evaluating the efficacy and safety of the combination of tagraxofusp and venetoclax in treatment-naive blastic pla… Recruiting

2024-511003-42-00 BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASMS 4 2025-12-11
Phase II RAINSPOT: a multicentric open label trial of Zolbetuximab-Paclitaxel-Ramucirumab in second line setting for CLDN18.2 positive gast… Recruiting

2025-521358-41-00 CLDN18.2 positive gastro-esophageal adenocarcinoma 4 2025-12-11
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma Recruiting

2024-513619-28-00 Clear Cell Renal Cell Carcinoma 1 2025-12-11
An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negat… Recruiting

2024-519913-76-00 PDL1-negative metastatic triple-negative breast cancer 4 2025-12-09
Phase II study of tarlatamab as a follow-up treatment after chemo and radiation in patients with small cell lung cancer (SCLC) who cannot re… Recruiting

2024-515201-26-00 Small cell lung cancer (SCLC) 4 2025-12-09
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System … Recruiting

2024-519493-39-00 High-risk Non-muscle-invasive Bladder Cancer with Susce 5 2025-12-09
A Multicenter, Open-label, Randomized Phase 3 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) vs Investigator Choice of Single-ag… Recruiting

2024-520164-33-00 Non-Small Cell Lung Cancer 5 2025-12-09
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous… Recruiting

2025-520730-28-00 Common EGFR-Mutated Locally Advanced or Metastatic Non- 4 2025-12-08
FUTURE Recruiting

2024-517573-24-00 Colorectal cancer 4 2025-12-08
A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-033) Recruiting

2024-517136-21-00 Renal Cell Carcinoma 5 2025-12-05
A clinical study to test if an investigational treatment called BNT326 is safe and potentially beneficial when used alone or in combination … Recruiting

2024-517261-16-00 Advanced solid tumors 9 2025-12-05
A Phase 1b/2 study of GSK5764227 in combination with Standard of Care (SoC) or other agents in participants with advanced solid tumors Recruiting

2025-522274-37-00 Neoplasms 9 2025-12-03
Trial of Tepotinib compared to Standard Treatment in Patients with Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer Recruiting

2024-519971-25-00 Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer 5 2025-12-03
Prospective cohort involving repeated medical PET-CT imaging with a new radiotracer (FAPI) Recruiting

2024-512467-31-00 Non-metastatic Pancreatic ductal adenocarcinoma 9 2025-12-02
A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program… Recruiting

2025-521281-97-00 Non-Small Cell Lung Cancer (NSCLC) 5 2025-12-02
ProspectivE phase 0 pilot study, assessing potential prognostic and theranostic interest of 68Ga-PentiXafor PET-CT In metastatic triple neGa… Recruiting

2024-517658-90-00 triple-negative breast cancer 3 2025-12-01